Core Viewpoint - The company, Selys Medical Technology Group Co., Ltd., is undergoing changes in its business scope and governance structure, with a focus on expanding into new product categories and preparing for a shareholder meeting to approve these changes [2][4][6]. Group 1: Stock Performance - As of December 26, 2025, Selys Medical's stock closed at 21.48 yuan, down 4.06% from the previous week's 22.39 yuan [1]. - The stock reached a high of 22.5 yuan and a low of 21.16 yuan on December 25, 2025 [1]. - The company's current total market capitalization is 4.515 billion yuan, ranking 24th out of 32 in the pharmaceutical commercial sector and 3628th out of 5178 in the A-share market [1]. Group 2: Corporate Announcements - The fifth board of directors held its 24th meeting on December 22, 2025, where it approved two key resolutions: one to expand the company's business scope and another to convene the first extraordinary general meeting of shareholders in 2026 [2][4]. - The company plans to hold the first extraordinary general meeting of shareholders on January 7, 2026, with both on-site and online voting options available [3][6]. - The proposed expansion of the business scope includes health products, cosmetics, daily chemical products, personal hygiene products, special medical purpose formula foods, pre-packaged foods, health foods, and internet sales [4][6]. Group 3: Corporate Governance - The company's articles of association were revised in December 2025, establishing it as a perpetual joint-stock company with a registered capital of 210,139,246 yuan [5]. - The articles outline shareholder rights and obligations, the powers and rules of the shareholders' meeting, responsibilities of the board of directors and supervisors, and financial accounting policies [5]. - The company aims for a cash dividend priority in profit distribution, with a commitment to distribute no less than 30% of the average distributable profit over the last three years [5].

Core Viewpoint - The investigation of Gao Yuwen, former chairman of China National Pharmaceutical Group Co., Ltd. (China Pharmaceutical), highlights ongoing corruption issues within the company, which has seen a significant decline in performance over recent years despite leadership changes. Group 1: Leadership and Governance - Gao Yuwen served as chairman for approximately three years and was the highest-ranking official investigated among over ten executives scrutinized in recent anti-corruption efforts [2][3] - Since 2016, China Pharmaceutical has experienced five chairmen, indicating instability in leadership without corresponding improvements in company performance [8][9] Group 2: Financial Performance - In the first three quarters of this year, China Pharmaceutical reported a net profit of approximately 455 million yuan, marking a decline of 4.64% year-on-year and the lowest level in nearly a decade [11][12] - The company's total revenue for the same period was 25.894 billion yuan, down 3.42% year-on-year, continuing a trend of revenue decline for two consecutive years [11][12] Group 3: Market Challenges - The company faces ongoing challenges from policies such as volume-based procurement and medical insurance cost control, which have pressured profit margins [11] - International trade revenue decreased by nearly 20% year-on-year, attributed to the impact of domestic substitution policies [11] Group 4: Strategic Initiatives - To address performance issues, the company is focusing on transformation and innovation, with planned R&D investments of 276 million yuan and 346 million yuan for 2023 and 2024, respectively [11] - The company has significantly reduced sales expenses from 2.485 billion yuan in 2020 to 1.099 billion yuan in 2024 as part of its compliance efforts [11] Group 5: Goodwill and Acquisitions - Previous acquisitions aimed at expanding the pharmaceutical commercial sector have resulted in goodwill risks, with a goodwill impairment loss of approximately 128 million yuan anticipated for 2024 [12] - As of the first three quarters of this year, the company's goodwill balance stood at 996 million yuan, compared to a net profit of 535 million yuan last year [12]

Core Viewpoint - The investigation of Gao Yuwen, former chairman of China National Pharmaceutical Group, is linked to serious violations of discipline and law, and he is currently under disciplinary review and investigation by the Central Commission for Discipline Inspection and the National Supervisory Commission [1][3] Group 1: Company Background and Leadership Changes - Gao Yuwen resigned from his position as chairman of China National Pharmaceutical Group in February 2021 due to work adjustments and has not held any company positions since then [1] - China National Pharmaceutical Group, established in 1983, became part of the General Technology Group in 1999 and is now the sole platform for pharmaceuticals and medical devices under the group [1] Group 2: Internal Investigations and Corruption - Since 2024, at least 11 executives or former executives from China National Pharmaceutical Group and its subsidiaries have been investigated for serious violations of discipline and law [2] - Li Xin, former assistant to the general manager, is also under investigation, having retired in October 2022 but continuing to hold other positions within the company [2] - Multiple subsidiaries, including Hebei General Huachuang Medical Equipment Co., Ltd. and Hubei General Pharmaceutical Co., Ltd., have seen executives investigated, with Hubei General Pharmaceutical having the highest number of four individuals under investigation [2] Group 3: Financial Performance - In 2024, the company reported a revenue of 34.148 billion yuan, a year-on-year decrease of 12.04%, and a net profit attributable to shareholders of 535 million yuan, down 48.91% [4] - For the first half of 2025, the company achieved a revenue of 17.076 billion yuan, a decline of 6.71%, and a net profit of 294 million yuan, down 16.19% [4] - In the first three quarters of 2025, the net profit attributable to shareholders was 477 million yuan, reflecting a year-on-year decrease of 4.64% [4]

证券日报网讯12月26日，建发致新（301584）在互动平台回答投资者提问时表示，截至最近一次查询日 12月19日，公司股东数量为28857户。 ...

每经头条（nbdtoutiao）——对话马斯克脑机接口"一号受试者"：大脑植入芯片23个月，我正重新夺回 人生的独立 每经AI快讯，海王生物（SZ 000078，收盘价：3.6元）12月26日晚间发布公告称，截至目前，公司累计 担保余额约为人民币45.09亿元，约占公司2024年度经审计合并报表净资产的比例为158.55%，不存在逾 期担保的情况。 2025年1至6月份，海王生物的营业收入构成为：医药商业流通占比62.16%，医疗器械流通占比 34.84%，医药制造占比1.96%，保健品和食品占比0.58%，其他业务占比0.46%。 截至发稿，海王生物市值为95亿元。 （记者 王瀚黎） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

证券之星消息，12月26日医药商业板块较上一交易日上涨0.04%，漱玉平民领涨。当日上证指数报收于 3963.68，上涨0.1%。深证成指报收于13603.89，上涨0.54%。医药商业板块个股涨跌见下表： 从资金流向上来看，当日医药商业板块主力资金净流出1.79亿元，游资资金净流出1.12亿元，散户资金净 流入2.91亿元。医药商业板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600538 | 国发股份 | 6.19 | -2.52% | 10.90万 | 6862.14万 | | 603716 | 塞力医疗 | 21.48 | -2.45% | 12.88万 | 2.79亿 | | 603122 | 合富中国 | 25.48 | -2.15% | 71.15万 | 18.16 Z | | 301408 | 华人健康 | 19.45 | -1.52% | 40.77万 | 8.01亿 | | 301584 | 建发致新 | 31.13 | -1.39% | 5.04 ...

Core Viewpoint - Ruikang Pharmaceutical has terminated its cooperation with Zhongxing Caiguanghua Accounting Firm and appointed Shenzhen Jiuan to undertake the 2025 audit, raising concerns about potential audit risks and independence issues [3][4]. Group 1: Company Actions - The company announced the change in auditors on December 24, citing "comprehensive consideration of business development and audit needs" without providing further details [3]. - The decision to change auditors comes just before the annual audit process, which typically starts in January and concludes by the end of April [3]. Group 2: Regulatory Issues - Ruikang Pharmaceutical has faced multiple regulatory warnings over the past five years, including a warning from the Shandong Securities Regulatory Bureau in December 2023 for serious violations [3]. - Specific violations include failing to disclose a 4.6 billion yuan related party transaction and not timely reporting litigation matters totaling 5.84 billion yuan [3]. Group 3: Management Turmoil - In July 2023, the company experienced significant management changes, including the detention of a board member and the resignation of the actual controller's son [4]. - These management upheavals coincide with a decline in the company's operational performance [4]. Group 4: Financial Performance - Revenue for Ruikang Pharmaceutical has seen significant declines from 2020 to 2024, with year-on-year decreases of 22.84%, 22.67%, 41.54%, 34.74%, and a slight drop of 0.85% in 2025 [4]. - The net profit for the company has also deteriorated, with a 63% year-on-year decline in the first three quarters of 2025 [4]. Group 5: Industry Context - Ruikang Pharmaceutical is not alone in terminating its relationship with Zhongxing Caiguanghua; at least 30 other A-share companies have also ended their partnerships with the firm amid concerns over its audit practices [5][6]. - The wave of terminations is linked to Zhongxing Caiguanghua's involvement in a financial fraud case, which has led to regulatory scrutiny and investigations [6].

证券日报网讯 12月25日，嘉事堂在互动平台回答投资者提问时表示，截至2025年12月19日，公司股东 共24000余户。 （文章来源：证券日报） ...

证券日报网讯12月25日，嘉事堂（002462）在互动平台回答投资者提问时表示，公司今年已取得由中质 协质量保证中心颁发的《合规管理体系认证证书》(证书编号：00625CMS20005ROM)。本次获得合规 管理体系认证证书，标志着公司合规管理水平已接轨国际标准，积极践行合规创造价值的理念，还将持 续深耕合规管理体系建设，为经营活动开展提供合规的管理保障。 ...

证券之星消息，12月25日医药商业板块较上一交易日上涨0.41%，合富中国领涨。当日上证指数报收于 3959.62，上涨0.47%。深证成指报收于13531.41，上涨0.33%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603122 | 合富中国 | 26.04 | 5.25% | 90.01万 | 22.46 乙 | | 301015 | 百洋医药 | 24.22 | 2.98% | 7.45万 | 1.80亿 | | 600538 | 国发股份 | 6.35 | 2.58% | 9.20万 | 5782.41万 | | 300937 | 药易购 | 35.16 | 2.36% | 11.03万 | 3.89亿 | | 002788 | 營荷医药 | 20.06 | 2.09% | 101.86万 | 19.77亿 | | 603716 | 塞力医疗 | 22.02 | 1.71% | 20.62万 | 4.51亿 | | 603939 | 益丰药房 | ...